FcγRIIIA receptor genotype does not influence an outcome in patients with follicular lymphoma treated with risk-adapted immunochemotherapy

Neoplasma

Volumn 58, Issue 3, 2011, Pages 263-270

  Prochazka, V ^a   Papajik, T ^a   Gazdova, J ^a   Divoka, M ^a   Rozmanova, S ^a   Faber, E ^a   Raida, L ^a   Kucerova, L ^b   Langova, K ^b   Jarosova, M ^a   Indrak, K ^a  

^a UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^b PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Autologous transplantation; BCL2 IgH rearrangements; Chemotherapy; Fc R polymorphisms; Follicular lymphoma; Rituximab

Indexed keywords

BETA 2 MICROGLOBULIN; BLEOMYCIN; CD16 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; IFOSFAMIDE; MESNA; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROTEIN TYROSINE KINASE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; FC RECEPTOR; FCGR3A PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; DNA POLYMORPHISM; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE; AUTOTRANSPLANTATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; FEMALE; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECEPTORS, IGG; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79961102292     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_03_263     Document Type: Article

References (34)

1. GHIELMINI M, SCHMITZ SF, BURKI K, PICHERT G, BETTICHER DC et al. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000;11 Suppl 1:123-6. doi:10.1023/A:1008301432453
2. MARCUS R, IMRIE K, Solal-Celigny P, CATALANO JV, DMOSZYNSKA A et al. Phase III study of R-CVP com- pared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-86. doi:10.1200/JCO.2007.13.5376
3. HIDDEMANN W, KNEBA M, DREYLING M, SCHMITZ N, LENGFELDER E et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low- Grade Lymphoma Study Group. Blood 2005;106:3725-32. doi:10.1182/blood-2005-01-0016
4. SCHULZ H, BOHLIUS JF, TRELLE S, SKOETZ N, REISER M et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706-14. doi:10.1093/jnci/djk152
5. CARTRON G, BLASCO H, PAINTAUD G, WATIER H, LE GUELLEC C. Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 2007;62:43-52. doi:10.1016/j.critrevonc.2006.09.004
6. CARTRON G, WATIER H, GOLAY J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004;104:2635-42. doi:10.1182/blood-2004- 03-1110
7. DALL'OZZO S, TARTAS S, PAINTAUD G, CARTRON G, COLOMBAT P et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004;64:4664-9. doi:10.1158/0008-5472.CAN-03-2862
8. HATJIHARISSI E, XU L, SANTOS DD, HUNTER ZR, Cic-Carelli BT et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 2007;110:2561-4. doi:10.1182/ blood-2007-01-070656
9. BOWLES JA, WEINER GJ. CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. J Immunol Methods 2005;304:88-99. doi:10.1016/j.jim.2005.06.018
10. BOWLES JA, WANG SY, LINK BK, ALLAN B, Beuer-Lein G et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006;108:2648-54. doi:10.1182/blood-2006-04-020057
11. WENG WK, LEVY R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7. doi:10.1200/JCO.2003.05.013
12. CARLOTTI E, PALUMBO GA, OLDANI E, TIBULLO D, SALMOIRAGHI S et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica 2007;92:1127-30. doi:10.3324/haematol.11288
13. PERSKY DO, DORNAN D, GOLDMAN BH, BRAZIEL RM, FISHER RI et al. Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Pa- tients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone. Blood (ASH Annual Meeting Abstracts) 114: 111.
14. DECAUDIN D, LEPAGE E, BROUSSE N, BRICE P, HAROUSSEAU JL et al. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte. J Clin Oncol 1999;17:2499-505.
15. FISHER RI, GAYNOR ER, DAHLBERG S, OKEN MM, GROGAN TM et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6. doi:10.1056/NEJM199304083281404
16. FEDERICO M, CLO V, BRUGIATELLI M, CAROTENUTO M, GOBBI PG et al. Efficacy of two different ProM- ACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Haematologica 1998;83:800-11.
17. PROCHAZKA V, FABER E, RAIDA L, VONDRAKOVA J, KUCEROVA L et al. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell trans- plantation. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009;153:63-6.
18. COLOMBAT P, BIRON P, LAPORTE JP, CAHN JY, HERVE P et al. BEAM protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas. Eur J Cancer 1990;26:858. doi:10.1016/0277-5379(90)90180-2
19. CHESON BD, HORNING SJ, COIFFIER B, SHIPP MA, FISHER RI et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
20. KOENE HR, KLEIJER M, ALGRA J, ROOS D, VON DEM BA et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997;90:1109-14.
21. CARTRON G, DACHEUX L, SALLES G, Solal-Celigny P, BARDOS P et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8. doi:10.1182/blood.V99.3.754
22. NIE HH, HADLAI H, JENKINS JG, STEINBRENNER K, BENT DH. SPSS (Statistical Package for the Social Sciences). New York, NY: McGraw-Hill, 1979.
23. KAPLAN EL, MEIER P. Non parametric estimation from incomplete observation. JAMA 1958;53: 457-481.
24. WENG WK, WENG WK, LEVY R. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma 2009;50:1494-500. doi:10.1080/10428190903128660
25. KIM DH, JUNG HD, KIM JG, LEE JJ, YANG DH et al. FCGR3A gene polymorphisms may correlate with re- sponse to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720-5. doi:10.1182/blood-2006-01-009480
26. ZHANG W, WANG X, LI J, DUAN MH, ZHOU DB. Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma. Chin Med J (Engl) 2010;123:198-202.
27. AHLGRIMM M, REGITZ E, PREUSS KD, GRASS S, POESCHEL V et al. Single Nucleotide Polymorphisms (SNPs) of FC RIIA and FC RIIIA in Patients with Diffuse Large B-Cell Lymphoma Have No Impact On Treatment Outcome of Elderly Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP with and without Rituximab: Results From the RICOVER-60 Trial of the German High- Grade Non-Hodgkin Lymhoma Study Group (DSHNHL). Blood (ASH Annual Meeting Abstracts) 114: 3956.
28. MITROVIC Z, AURER I, RADMAN I, AJDUKOVIC R, SERTIC J et al. FCgammaRIIIA and FCgammaRIIA poly- morphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Hae- matologica 2007;92:998-9. doi:10.3324/haematol.10327
29. CASTILLO J, WINER E, QUESENBERRY P. Newer monoclonal antibodies for hematological malignancies. Exp Hematol 2008;36:755-68. doi:10.1016/j.exphem.2008.04.018
30. ROBAK T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 2009;10:588-96.
31. O'BRIEN S, OSTERBORG A. Ofatumumab: a new CD20 monoclonal antibody therapy for B-cell chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk 2010;10:361-8. doi:10.3816/CLML.2010.n.069
32. CERHAN JR, WANG S, MAURER MJ, ANSELL SM, GEYER SM et al. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood 2007;109:5439-46. doi:10.1182/blood-2006-11-058040
33. WANG SS, PURDUE MP, CERHAN JR, ZHENG T, MENASHE I et al. Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-kB transcription factors and non-Hodgkin lymphoma risk. PLoS One 2009;4:e5360. doi:10.1371/journal. pone.0005360
34. WENG WK, NEGRIN RS, LAVORI P, HORNING SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010;28:279-84. doi:10.1200/JCO.2009.25.0274